Pipeline

Our Catalog of Medicines in Development

By leveraging cutting-edge technology, rigorous and validated science and strategic partnerships across the healthcare ecosystem, we’re aiming to develop medicines more efficiently and cost-effectively than ever before. We believe it’s possible to greatly expand access to new, high-quality, patent-protected therapeutics.

EQRx’s growing portfolio of medicines in development is targeting diseases and therapeutic classes that create a high cost burden to patients and society. Our clinical stage programs span several indications in oncology and immune-inflammatory diseases.

Investigational Program
Target
Preclinical
Phase 1
Phase 2
Phase 3
Approval

Aumolertinib

EQ143, HS-10296

EGFR

EGFR-mutated non-small cell lung cancer

Phase 3

Aumolertinib (EQ143, HS-10296) is a third-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets both EGFR-sensitizing and T790M resistance mutations, with high selectivity over wild-type EGFR. Aumolertinib was in-licensed from Hansoh Pharmaceuticals.

Sugemalimab

EQ165, CS1001

PD-L1

Stage III non-small cell lung cancer

Phase 3

Stage IV non-small cell lung cancer

Phase 3

Relapsed/refractory extranodal NK/T-cell lymphoma

Phase 2

Sugemalimab (EQ165, CS1001) is a monoclonal antibody targeting programmed death-ligand 1 (PD-L1). Sugemalimab was in-licensed from CStone Pharmaceuticals.

Nofazinlimab

EQ176, CS1003

PD-1

Hepatocellular carcinoma

Phase 3

Nofazinlimab (EQ176, CS1003) is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). Nofazinlimab was in-licensed from CStone Pharmaceuticals.

Lerociclib

EQ132

CDK4/6

Metastatic breast cancer

Phase 3

Lerociclib (EQ132) is a novel, oral, potent and selective small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Lerociclib was in-licensed from G1 Therapeutics.

EQ121

JAK1

Immune-inflammatory indications

Phase 2

EQ-121 is a novel, highly selective janus kinase-1 (JAK-1) inhibitor. EQ121 was in-licensed from Lynk Pharmaceuticals.

This pipeline describes investigational assets as of May 13, 2022. The safety and efficacy of these investigational assets have not been established.

There is no guarantee that the outcome of these studies will result in approval by a regulatory authority.

View our Expanded Access Policy.